CO7000770A2 - Terapia combinada para el tratamiento del cáncer de ovario - Google Patents

Terapia combinada para el tratamiento del cáncer de ovario

Info

Publication number
CO7000770A2
CO7000770A2 CO14139058A CO14139058A CO7000770A2 CO 7000770 A2 CO7000770 A2 CO 7000770A2 CO 14139058 A CO14139058 A CO 14139058A CO 14139058 A CO14139058 A CO 14139058A CO 7000770 A2 CO7000770 A2 CO 7000770A2
Authority
CO
Colombia
Prior art keywords
treatment
ovarian cancer
combined therapy
patient
ovarian
Prior art date
Application number
CO14139058A
Other languages
English (en)
Inventor
Corrado Bernasconi
David Bollag
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47844333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7000770(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO7000770A2 publication Critical patent/CO7000770A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0241—Advertisements
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q90/00—Systems or methods specially adapted for administrative, commercial, financial, managerial or supervisory purposes, not involving significant data processing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Business, Economics & Management (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Strategic Management (AREA)
  • Finance (AREA)
  • Theoretical Computer Science (AREA)
  • Development Economics (AREA)
  • Accounting & Taxation (AREA)
  • General Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • Physics & Mathematics (AREA)
  • Economics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marketing (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Game Theory and Decision Science (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)

Abstract

Esta invención hace referencia a los métodos de tratamiento de una paciente diagnosticada de cáncer ovárico resistente al platino que incluye la administración a dicha paciente de una cantidad efectiva de un anticuerpo anti-VEGF y un quimioterapéutico.
CO14139058A 2012-03-13 2014-06-27 Terapia combinada para el tratamiento del cáncer de ovario CO7000770A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261610128P 2012-03-13 2012-03-13
US201261653598P 2012-05-31 2012-05-31
US201261672987P 2012-07-18 2012-07-18

Publications (1)

Publication Number Publication Date
CO7000770A2 true CO7000770A2 (es) 2014-07-21

Family

ID=47844333

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14139058A CO7000770A2 (es) 2012-03-13 2014-06-27 Terapia combinada para el tratamiento del cáncer de ovario

Country Status (31)

Country Link
US (2) US20150098988A1 (es)
EP (2) EP3553083A1 (es)
JP (2) JP6563197B2 (es)
KR (1) KR102082363B1 (es)
CN (1) CN104334577A (es)
AR (1) AR090313A1 (es)
AU (2) AU2013231410B2 (es)
BR (1) BR112014018964A2 (es)
CA (2) CA2860941C (es)
CO (1) CO7000770A2 (es)
CR (1) CR20140400A (es)
CY (1) CY1121821T1 (es)
DK (1) DK2825558T3 (es)
EA (1) EA201400996A1 (es)
ES (1) ES2736030T3 (es)
HK (1) HK1202122A1 (es)
HR (1) HRP20191248T1 (es)
HU (1) HUE045445T2 (es)
IL (2) IL234174B (es)
LT (1) LT2825558T (es)
MX (1) MX365139B (es)
PE (1) PE20141909A1 (es)
PH (1) PH12014501543A1 (es)
PL (1) PL2825558T3 (es)
PT (1) PT2825558T (es)
RS (1) RS58964B1 (es)
SG (1) SG11201404417PA (es)
SI (1) SI2825558T1 (es)
TW (1) TW201343178A (es)
WO (1) WO2013135602A2 (es)
ZA (1) ZA201404843B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3485903B1 (en) 2011-09-23 2022-11-16 Mereo BioPharma 5, Inc. Vegf/dll4 binding agents and uses thereof
DK2825558T3 (da) 2012-03-13 2019-07-22 Hoffmann La Roche Kombinationsterapi til behandling af ovariecancer
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN109071644B (zh) * 2015-09-23 2023-09-19 昂考梅德药品有限公司 治疗癌症的方法和组合物
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
US20200121703A1 (en) * 2017-06-26 2020-04-23 The Cleveland Clinic Foundation Cancer treatment
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN115814076A (zh) * 2021-07-01 2023-03-21 江苏先声药业有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
CN117940164A (zh) * 2022-04-26 2024-04-26 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
DE69232539T3 (de) 1992-10-28 2007-01-04 Genentech, Inc., South San Francisco Verwendung von anti-VEGF Antikörpern zur Behandlung von Krebs
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
EP1516628B1 (en) 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
SI1325932T1 (es) 1997-04-07 2005-08-31 Genentech Inc
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE69841815D1 (de) 1997-04-07 2010-09-16 Genentech Inc Anti-VEGF Antikörper
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
DE69926536T3 (de) 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
CA2393869A1 (en) 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
KR20060006975A (ko) 2003-05-30 2006-01-20 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
SI1784426T1 (sl) 2004-09-03 2012-03-30 Genentech Inc Humanizirani antagonisti proti beta in njihove uporabe
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
TR200905706T1 (tr) * 2006-12-20 2009-12-21 J-C Health Care Ltd. Pegile edilmiş lipozomal doksorubisinin uygulanması için usul
JP2010518013A (ja) 2007-02-01 2010-05-27 ジェネンテック， インコーポレイテッド 血管形成阻害剤を含む組み合わせ治療の方法
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
WO2009149150A2 (en) * 2008-06-03 2009-12-10 Alza Corporation Composition comprising liposome-entrapped doxorubicin and methods of administration
JP6041489B2 (ja) 2008-11-22 2016-12-07 ジェネンテック， インコーポレイテッド 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用
US20190185555A1 (en) 2017-12-19 2019-06-20 Genentech, Inc. Anti-angiogenesis therapy for the treatment of previously treated breast cancer
CN103237810A (zh) 2010-02-23 2013-08-07 霍夫曼-拉罗奇有限公司 用于治疗卵巢癌的抗血管发生疗法
DK2825558T3 (da) 2012-03-13 2019-07-22 Hoffmann La Roche Kombinationsterapi til behandling af ovariecancer

Also Published As

Publication number Publication date
CR20140400A (es) 2014-10-07
US11384142B2 (en) 2022-07-12
MX2014010591A (es) 2014-09-18
CA2860941A1 (en) 2013-09-19
JP6640288B2 (ja) 2020-02-05
SG11201404417PA (en) 2014-10-30
CA2860941C (en) 2019-11-05
KR102082363B1 (ko) 2020-02-27
HRP20191248T1 (hr) 2019-10-18
EP2825558B1 (en) 2019-05-15
JP6563197B2 (ja) 2019-08-21
PT2825558T (pt) 2019-07-11
CY1121821T1 (el) 2020-10-14
US20160289317A1 (en) 2016-10-06
WO2013135602A2 (en) 2013-09-19
MX365139B (es) 2019-05-24
WO2013135602A3 (en) 2013-11-07
IL234174B (en) 2019-01-31
DK2825558T3 (da) 2019-07-22
CA3056813A1 (en) 2013-09-19
EP3553083A1 (en) 2019-10-16
AU2013231410A1 (en) 2014-07-17
PH12014501543A1 (en) 2014-10-08
ES2736030T3 (es) 2019-12-23
IL263781A (en) 2019-01-31
AU2017258927A1 (en) 2017-11-30
PE20141909A1 (es) 2014-11-29
KR20140138691A (ko) 2014-12-04
BR112014018964A8 (pt) 2017-07-11
AR090313A1 (es) 2014-11-05
BR112014018964A2 (pt) 2020-05-12
TW201343178A (zh) 2013-11-01
LT2825558T (lt) 2019-08-12
CN104334577A (zh) 2015-02-04
ZA201404843B (en) 2015-08-26
HK1202122A1 (en) 2015-09-18
EA201400996A1 (ru) 2015-03-31
US20150098988A1 (en) 2015-04-09
JP2015511593A (ja) 2015-04-20
KR102082363B9 (ko) 2023-05-02
SI2825558T1 (sl) 2019-08-30
HUE045445T2 (hu) 2019-12-30
EP2825558A2 (en) 2015-01-21
RS58964B1 (sr) 2019-08-30
AU2013231410B2 (en) 2017-08-17
PL2825558T3 (pl) 2019-11-29
JP2018193380A (ja) 2018-12-06

Similar Documents

Publication Publication Date Title
CO7000770A2 (es) Terapia combinada para el tratamiento del cáncer de ovario
CL2017000554A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
BR112016010271A2 (pt) Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
CR20140357A (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CU20150128A7 (es) Conjugados fármaco-anticuerpo
CO2017001191A2 (es) Conjugados de fármacos con anticuerpos anti-cdh6
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
UY35399A (es) Conjugados de fármacos con anticuerpos
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
CR20120522A (es) Pirrolobenzodiacepinas y conjugados de las mismas
CR20150316A (es) Compuestos y sus métodos de empleo
BR112016000903A2 (pt) anticorpos
AR091837A1 (es) Compuestos para inmunoterapia dirigida
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
UY36075A (es) Derivados de tubulisina
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
AR096183A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco
BR112012016820A2 (pt) Metodos para tratamento de cancer de seio
BR112015023098A2 (pt) agentes de infrarregulação do receptor de andrógeno e usos dos mesmos
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
CL2015002479A1 (es) Composición farmacéutica que comprende unión de la arginina albúmina-vinculante para suspender la focalización del tratamiento del cáncer.
AR077867A1 (es) Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer

Legal Events

Date Code Title Description
FA Application withdrawn